Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Carlsson

Showing results (451-460 of 492) with videos related to

Pageof 50
Sort By:
Atherosclerosis|July 24, 2020
The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney diseaseTobias Feldreich, Christoph Nowak, Axel C Carlsson, et al.
Endocrinology|June 1, 1996
Increased amounts of a high molecular weight insulin-like growth factor II (IGF-II) peptide and IGF-II messenger ribonucleic acid in pancreatic islets of diabetic Goto-Kakizaki ratsA Höög, A C Sandberg-Nordqvist, S M Abdel-Halim, et al.
Atherosclerosis|April 9, 2019
Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-studyToralph Ruge, Axel C Carlsson, Erik Kjøller, et al.
Journal of the American Heart Association|April 25, 2018
10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial SubstudyAxel C Carlsson, Toralph Ruge, Erik Kjøller, et al.
Atherosclerosis|September 28, 2018
Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-studyJonas Wuopio, Jørgen Hilden, Carl Bring, et al.
Molecular & Cellular Proteomics : MCP|November 13, 2014
Glycoproteomic analysis of seven major allergenic proteins reveals novel post-translational modificationsAdnan Halim, Michael C Carlsson, Caroline Benedicte Madsen, et al.
Journal of Nephrology|December 1, 2018
Circulating proteins as predictors of cardiovascular mortality in end-stage renal diseaseTobias Feldreich, Christoph Nowak, Tove Fall, et al.
The Journal of Biological Chemistry|September 3, 2010
Mutational tuning of galectin-3 specificity and biological functionEmma Salomonsson, Michael C Carlsson, Veronica Osla, et al.
Preventive Medicine Reports|September 12, 2019
An evidence-based toolbox for the design and implementation of selective-prevention primary-care initiatives targeting cardio-metabolic diseaseAnders Larrabee Sonderlund, Trine Thilsing, Joke Korevaar, et al.
European Journal of Preventive Cardiology|June 20, 2018
Barriers and facilitators to participation in a health check for cardiometabolic diseases in primary care: A systematic reviewAnne-Karien M de Waard, Per E Wändell, Martin J Holzmann, et al.
Pageof 50

Showing results (451-460 of 492) with videos related to

Sort By:
Pageof 50
Atherosclerosis|July 24, 2020
The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney diseaseTobias Feldreich, Christoph Nowak, Axel C Carlsson, et al.
Endocrinology|June 1, 1996
Increased amounts of a high molecular weight insulin-like growth factor II (IGF-II) peptide and IGF-II messenger ribonucleic acid in pancreatic islets of diabetic Goto-Kakizaki ratsA Höög, A C Sandberg-Nordqvist, S M Abdel-Halim, et al.
Atherosclerosis|April 9, 2019
Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-studyToralph Ruge, Axel C Carlsson, Erik Kjøller, et al.
Journal of the American Heart Association|April 25, 2018
10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial SubstudyAxel C Carlsson, Toralph Ruge, Erik Kjøller, et al.
Atherosclerosis|September 28, 2018
Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-studyJonas Wuopio, Jørgen Hilden, Carl Bring, et al.
Molecular & Cellular Proteomics : MCP|November 13, 2014
Glycoproteomic analysis of seven major allergenic proteins reveals novel post-translational modificationsAdnan Halim, Michael C Carlsson, Caroline Benedicte Madsen, et al.
Journal of Nephrology|December 1, 2018
Circulating proteins as predictors of cardiovascular mortality in end-stage renal diseaseTobias Feldreich, Christoph Nowak, Tove Fall, et al.
The Journal of Biological Chemistry|September 3, 2010
Mutational tuning of galectin-3 specificity and biological functionEmma Salomonsson, Michael C Carlsson, Veronica Osla, et al.
Preventive Medicine Reports|September 12, 2019
An evidence-based toolbox for the design and implementation of selective-prevention primary-care initiatives targeting cardio-metabolic diseaseAnders Larrabee Sonderlund, Trine Thilsing, Joke Korevaar, et al.
European Journal of Preventive Cardiology|June 20, 2018
Barriers and facilitators to participation in a health check for cardiometabolic diseases in primary care: A systematic reviewAnne-Karien M de Waard, Per E Wändell, Martin J Holzmann, et al.
Pageof 50